Hello, everyone, and how are you today? We are doing just fine, thank you, especially as we are helped along by a bright, shiny sun enveloping the serene Pharmalot campus. Our shortest person has left for the local schoolhouse and the official mascots are sunning themselves in the parlor. As for us, we are as busy as ever, foraging for interesting items. Speaking of which, here are a few. Hope you have a lovely day and do keep in touch …
Hanmi Pharmaceutical belatedly reported a fatal side effect in a patient during clinical trials of its lung cancer drug Olita Tab, the Korea Herald tells us. The Board of Audit and Inspection of Korea said the drug maker broke two medical laws regarding the monitoring and reporting of its clinical trials. The board had opened an investigation after some lawmakers charged Hanmi of intentionally delaying reporting to win approval for the drug.
Satish Mehta appears to be the next target in a US probe into generic drug price gouging and is using an aggressive preemptive strategy to fight back, Forbes writes. His team is trying to portray Jeff Glazer, the former chief executive at Heritage Pharmaceuticals, as an unreliable rat. Glazer pleaded guilty to violating US antitrust law and his deal says he conspired with his bosses in India. Mehta heads Emcure Pharmaceuticals, which owns Heritage.
About the Author Reprints
